Psoriasis - infliximab (TA134)
Fast, easy summary view of NICE guidance on 'psoriasis'
Infliximab is recommended as a possible treatment for adults with plaque psoriasis only if:
- their condition is very severe and
- their condition has not improved with other treatments such as ciclosporin, methotrexate or PUVA (psoralen and long-wave ultraviolet radiation), or they have had side effects with these inthe past or there is a medical reason why they should not be given these treatments.
Infliximab treatment should be continued beyond 10 weeks only if the psoriasis has clearly improved within this time.
The severity of a person's psoriasis before and during treatment should be assessed by considering the redness, thickness and scaliness of the plaques, the area of the body involved, and how the condition affects the person's quality of life.
When assessing a person's psoriasis, healthcare professionals should take into account any disabilities or difficulties in communicating, which might mean that the standard assessments do not provide accurate information about their condition.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: psoriasis
This page was last updated: 19 October 2012
Information for the public
Implementation tools and resources
- Audit support
- Costing template
- Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology commissioning guide
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.